News & Events
Sengenics KREX™ technology acquired by Standard BioTools Inc.
Webinar: Predicting Therapy Outcomes with Autoantibody Biomarkers in Melanoma
Sengenics Corporation at Biomarkers US 2024
Sengenics Corporation Presents at HUPO World Congress 2024
Sengenics Corporation Exhibits at Biomarkers Europe 2024
Sengenics Corporation Presents at Microbiome Drug Development Online Symposium 2024
Sengenics Corporation Launches i-Ome® Cancer for Immune Response Profiling in Cancer Research
Sengenics Corporation at Immuno-Oncology Summit 2024
Webinar: Serum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups
"*" indicates required fields
By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy. I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.
Δ
"*" Indicates required fields By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy. I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.